Vizamyl
Generic name: flutemetamol F18 injection
Drug class: Diagnostic radiopharmaceuticals
Approval date: October 25, 2013
Company: GE Healthcare
What is Vizamyl?
Vizamyl is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD), other causes of cognitive decline, or in a selection of patients suitable for amyloid beta-directed treatment as described in the prescribing information for those products.
Indications and Uses of Vizamyl
Negative Vizamyl Scan:
- Shows a clear contrast between white matter (bright) and gray matter (darker)
- Key regions have low uptake (below 50-60% peak intensity)
- Indicates sparse to no amyloid plaques
- In untreated patients, inconsistent with Alzheimer's disease diagnosis and reduces likelihood that cognitive impairment is due to AD
- Does not rule out future amyloid accumulation
Positive Vizamyl Scan:
- Shows reduced or lost contrast between gray and white matter
- At least one brain region has high gray matter uptake (above 50-60% peak intensity)
- Gray matter may appear as bright as or brighter than adjacent white matter
- Indicates moderate to frequent amyloid plaques are present
- Confirms amyloid plaques but doesn't definitively diagnose Alzheimer's - plaques can also occur in other neurologic conditions and normal aging
Key Point: Quantitative analysis can supplement visual assessment using FDA-authorized software for more precise measurements.
Contraindications
Known hypersensitivity to Vizamyl or any excipient, including polysorbate 80.
Warnings and Precautions
Hypersensitivity Reactions: Reactions such as flushing and dyspnea have been observed within minutes following administration and may occur in patients with no history of exposure to Vizamyl.
Image Misinterpretation: Errors may occur while interpreting Vizamyl PET images. Image interpretation is performed independently of the patient’s clinical information; the use of clinical information in the interpretation of Vizamyl images has not been evaluated and may lead to errors. Extensive brain atrophy may limit the ability to distinguish grey and white matter on a Vizamyl scan. Motion artifacts may distort the image. Images should be interpreted only by readers who have completed a reader training program available from GE Healthcare.
Radiation Risk: Like all radiopharmaceuticals, Vizamyl contributes to a patient’s long-term, cumulative radiation exposure. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure.
Vizamyl side effects
The most common side effects reported with Vizamyl are:
- flushing
- increased blood pressure
- headache
- nausea
- dizziness.
To report suspected side effects, contact GE HealthCare at 1-800-654-0118 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Related/similar drugs
Cerianna
Cerianna is used for diagnosis and investigation, positron emission tomography imaging
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Flyrcado
Flyrcado (flurpiridaz F 18) is a radioactive diagnostic drug that may be used for positron emission ...
Amyvid
Amyvid (florbetapir F 18) is used to detect plaque in the brain of patients who are being evaluated ...
Florbetaben f-18
Florbetaben f-18 is used for positron emission tomography imaging
Drug Interactions
Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Vizamyl image results.
Use in Specific Populations
Pregnancy: It is not known whether Vizamyl can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Radiopharmaceuticals, including Vizamyl, have the potential to cause fetal harm, the likelihood of which depends on the stage of fetal development and the magnitude of the radiopharmaceutical dose. Vizamyl should be given to a pregnant woman only if needed.
Nursing Mothers: Temporarily discontinue breastfeeding. A lactating woman should pump and discard breast milk for 24 hours after Vizamyl administration.
Pediatric Use: Vizamyl is not indicated for use in pediatric patients.
Geriatric Use: No overall differences in safety were observed between older and younger subjects.
Overdosage
The clinical consequence of overdose with Vizamyl has not been reported. It is unknown whether or not flutemetamol is dialyzable. In case of overdose of radioactivity, hydration and frequent urination should be encouraged.
Ingredients
Active ingredients: Each mL contains up to 2 mcg of flutemetamol and 150 MBq (4.05 mCi) of flutemetamol F 18 at reference date and time.
Inactive ingredients: 70 microL ethanol, 9 mg sodium chloride, and 4.98 mg polysorbate 80 (w/v) in 0.014 M aqueous phosphate buffer. The pH of the solution is between 6 and 8.5.
Vizamyl is supplied as an injection containing 150 MBq/mL (4.05 mCi/mL) of flutemetamol F 18 in up to 30 mL volume at reference date and time in a multiple-dose vial.
Manufacturer
Vizamyl is manufactured for GE Healthcare, Medi-Physics, Inc., Arlington Heights, IL 60004.
References
More about Vizamyl (flutemetamol f-18)
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: diagnostic radiopharmaceuticals
- Breastfeeding
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.